Results 31 to 40 of about 8,048 (135)
Canadian Journal of Kidney Health and Disease, 2018 Background: Autosomal dominant polycystic kidney disease (ADPKD) is the most common hereditary kidney disease, with afflicted patients often progressing to end-stage kidney disease (ESKD) requiring renal replacement therapy (RRT).
Brandon Budhram +9 more
doaj +1 more source
Clinical Pharmacology &Therapeutics, Volume 119, Issue 6, Page 1522-1536, June 2026.Traditionally, clinical outcomes measuring how a patient feels, functions, or survives are preferred endpoints in clinical trials; however, some may take a long time to manifest in slowly developing diseases. Biomarkers, if properly validated, can serve as surrogate endpoints, acting as substitutes for clinical outcomes.
Renske Johanna Grupstra +4 more
wiley +1 more source
Frontiers in Cell and Developmental Biology, 2020 Autosomal dominant polycystic kidney disease (ADPKD) is a complex process, involving the alteration of multiple genes and signaling pathways, and the pathogenesis of ADPKD remains largely unknown.
Ai-Wen Shen +8 more
doaj +1 more source
Clinical Transplantation, Volume 40, Issue 6, June 2026.ABSTRACT Background Pneumocystis jirovecii is an opportunistic fungus responsible for Pneumocystis pneumonia (PJP) in hosts with impaired cell‐mediated immunity, particularly solid organ transplant recipients. The aim of our study was to identify risk factors associated with PJP in kidney transplant recipients (KTRs).
Solenne Hulot +9 more
wiley +1 more source
Internal Medicine Journal, Volume 56, Issue 6, Page 966-975, June 2026.Abstract Background Chronic kidney disease (CKD) is a significant public health challenge in Australia, affecting ~10% of the adult population and contributing to substantial morbidity and mortality. Diabetes, hypertension, cardiovascular disease and CKD frequently co‐exist; therefore, a multidisciplinary approach is necessary to manage these ...
M. P. Schlaich +7 more
wiley +1 more source
Saudi Journal of Kidney Diseases and Transplantation, 2017 Hypertension is a common early finding in autosomal dominant polycystic kidney disease (ADPKD). Improvements in screening and diagnosis of ADPKD have allowed earlier diagnosis, later onset of end-stage renal disease, and better survival.
Imed Helal +3 more
doaj +1 more source
The FASEB Journal, Volume 40, Issue 9, 15 May 2026.Earlier in neurogenesis, knockdown of polycystin‐1 (PC1) expression increases the cell cycle length of neural progenitor cells (NPCs) by extending the S‐phase and probably lengthening the G1‐phase. Subsequently, reduced PC1 expression causes delayed cell cycle exit and delayed neuronal differentiation of NPCs.
Natalie Winokurow, Stefan Schumacher
wiley +1 more source
Deciphering the Impact of RAC1‐SPTAN1 in ARPKD Cystogenesis Using Multifaceted Models
Advanced Science, Volume 13, Issue 25, 4 May 2026.Distal/connecting tubules expressing SLC8A1 have been suggested as a potential origin of ARPKD cysts. SPTAN1 has been identified as a key molecule in ARPKD cyst formation. Restoring SPTAN1 in PKHD1−/− organoids reduced cyst formation, normalized calcium levels, and decreased RAC1/c‐FOS expression, highlighting SPTAN1's role in ARPKD and the potential ...
Shohei Kuraoka +9 more
wiley +1 more source
BMC Nephrology, 2019 Autosomal Dominant Polycystic Kidney Disease (ADPKD) is thought to affect about 1 in 1000 people in the UK. ADPKD causes a progressive decline in kidney function, with kidney failure tending to occur in middle age.
Jan Dudley +11 more
doaj +1 more source
Journal of Extracellular Vesicles, Volume 15, Issue 5, May 2026.This systematic review compiles and analyses 364 studies on chronic kidney disease (CKD) that investigated extracellular vesicles (EVs) for diagnostic and therapeutic applications. By systematically categorizing data according to EV source and cargo, it provides an integrated overview of EV application for CKD, highlighting common approaches and shared
Tunahan Ergunay +2 more
wiley +1 more source